These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23076599)

  • 21. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
    Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.
    Chen XY; Thike AA; Md Nasir ND; Koh VCY; Bay BH; Tan PH
    Virchows Arch; 2020 Jun; 476(6):825-833. PubMed ID: 31897820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biology of breast cancer in Nigerian women: a pilot study.
    Adisa CA; Eleweke N; Alfred AA; Campbell MJ; Sharma R; Nseyo O; Tandon V; Mukhtar R; Greninger A; Risi JD; Esserman LJ
    Ann Afr Med; 2012; 11(3):169-75. PubMed ID: 22684136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple-negative breast cancers: a view from 10,000 feet.
    Ray M; Polite BN
    Cancer J; 2010; 16(1):17-22. PubMed ID: 20164686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients.
    Xuan QJ; Wang JX; Nanding A; Wang ZP; Liu H; Lian X; Zhang QY
    Pathol Oncol Res; 2014 Jul; 20(3):619-24. PubMed ID: 24414992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical Expression of CD47 and CD68 in Breast Carcinoma and Their Prognostic Value.
    Alhanafy S; Hany H; Nasef K; El-Salkh I; Elhawary A
    Asian Pac J Cancer Prev; 2024 Jul; 25(7):2515-2527. PubMed ID: 39068587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome.
    Sullivan HC; Oprea-Ilies G; Adams AL; Page AJ; Kim S; Wang J; Cohen C
    Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):17-23. PubMed ID: 23455177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
    Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
    Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune cells within tertiary lymphoid structures are associated with progression-free survival in patients with locoregional recurrent breast cancer.
    Gu J; Wang J; Sun Y; Mao X; Qian C; Tang X; Wang J; Xie H; Ling L; Zhao Y; Liu X; Zhang K; Pan H; Wang S; Wang C; Zhou W
    Cancer Med; 2024 Jan; 13(1):e6864. PubMed ID: 38133211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study on local expression of NF-κB, CCL2 and their involvement in intratumoral macrophage infiltration in breast cancer.
    Tewari BN; Singh Baghel K; Tripathi C; Dubey P; Bhatt ML; Kumar V; Mati Goel M; Singh Negi MP; Misra S
    Cell Mol Biol (Noisy-le-grand); 2016 Feb; 62(2):116-25. PubMed ID: 26950462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone status and demographics in early onset breast cancer patients.
    Friend KE; Perry RR; Collins JN; Britt RC; Feliberti EC
    Am Surg; 2012 Jul; 78(7):819-21. PubMed ID: 22748546
    [No Abstract]   [Full Text] [Related]  

  • 32. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
    Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
    Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
    Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
    J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of age on race-related breast cancer survival disparities.
    Wray CJ; Phatak UR; Robinson EK; Wiatek RL; Rieber AG; Gonzalez A; Ko TC; Kao LS
    Ann Surg Oncol; 2013 Aug; 20(8):2541-7. PubMed ID: 23435633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma.
    Mwafy SE; El-Guindy DM
    J Egypt Natl Canc Inst; 2020 Jan; 32(1):6. PubMed ID: 32372332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does race predict survival for women with invasive breast cancer?
    Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML
    Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.